Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Predictive Value of 3 Months Results on 12 Months Tumor Shrinkage After First-Line Octreotide-LAR Therapy in Patients With Acromegaly

NCT00616408 is registered in ClinicalTrials.gov with Federico II University as lead sponsor.

NCT NCT00616408
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00616408 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Predictive Value of 3 Months Results on 12 Months Tumor Shrinkage After First-Line Octreotide-LAR Therapy in Patients With Acromegaly
Lead sponsor
Federico II University
Phase
Observational
Overall status
Completed
Start date
January 31, 1997
Completion date
December 31, 2007
Enrollment
61 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acromegaly